Equity Profile

RCUS

Arcus Biosciences, Inc.

Health CareBiotechnology$3.7B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Arcus Biosciences, Inc. (RCUS) is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a crucial indicator of the company's profitability and financial health, especially in the biotech sector where investors look for signs of progress.

N/A

Revenue Growth

Revenue growth is vital for assessing the company's ability to commercialize its products and sustain operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RCUS Q2-2026 Earnings Preview

Context

Company Snapshot

Arcus Biosciences, Inc. (RCUS) is a biotechnology company focused on developing innovative cancer therapies. With a market cap of $4 billion, it operates in the health care sector, which is increasingly important as demand for advanced treatments grows.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+15.06%

Avg Stock Reaction

-0.13%

Last Quarter Recap

In Q1 2026, Arcus reported an EPS of -$1.02, which was worse than the expected -$0.92, leading to a slight stock increase of 0.04% the following day. The company continues to face challenges in meeting revenue expectations.

Management Promises & Guidance

Focus on advancing clinical trials for key drug candidates.
Commitment to improving operational efficiency.
Plans to enhance investor communication regarding trial results.

Expectations

Wall Street Expectations

Overall, expectations for Arcus's upcoming earnings are mixed, with investors keenly watching for any signs of progress in clinical trials and financial performance. The lack of analyst estimates adds uncertainty.

Bull Case

If Arcus demonstrates significant progress in its clinical trials and manages to beat EPS expectations, it could lead to a strong positive reaction from investors.

Bear Case

Conversely, if the company fails to provide encouraging updates on its drug development or reports larger-than-expected losses, it could result in a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What updates can management provide on the progress of clinical trials for key drug candidates?

Investors will closely watch for any developments that could indicate the potential success of these therapies, which are crucial for the company's future.

How does the company plan to address its recent EPS misses and improve financial performance?

Understanding management's strategy for improving profitability will be critical for investor confidence and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of recent clinical trial results, which could lead to a more favorable outlook than currently anticipated.

Supporting Evidence

The options market is pricing a significant move, indicating that investors expect volatility and potential surprises.

The company's history of beating EPS estimates suggests that there may be more positive news than analysts expect.

Key Risk

If clinical trial results show unexpected promise, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to turn clinical advancements into financial success.

Bull Confirmed If

A significant improvement in clinical trial results or an EPS beat could confirm the bull case.

Bear Confirmed If

A larger-than-expected EPS loss or disappointing trial updates would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±33.48%

Historical Avg

±2.9%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±33.5% while RCUS has averaged ±2.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

56.4%

Calls (400)P/C Ratio: 0.40Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arcus beats expectations, history suggests the stock could rise by an average of 1.35%, confirming investor optimism about its drug pipeline.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.

Miss

If the company misses expectations, history suggests a potential decline of around 4.57%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the progress of clinical trials and any upcoming milestones.
2Management's strategy for improving financial performance.
3Insights into potential partnerships or collaborations.
4Updates on market conditions and competitive landscape.
5Any changes in guidance or future outlook.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Arcus Biosciences, Inc. (RCUS) is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a crucial indicator of the company's profitability and financial health, especially in the biotech sector where investors look for signs of progress.

N/A

Revenue Growth

Revenue growth is vital for assessing the company's ability to commercialize its products and sustain operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RCUS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+15.06%

Avg Stock Reaction

-0.13%

Last Quarter Recap

Management Promises & Guidance

Focus on advancing clinical trials for key drug candidates.
Commitment to improving operational efficiency.
Plans to enhance investor communication regarding trial results.

Expectations

Wall Street Expectations

Bull Case

If Arcus demonstrates significant progress in its clinical trials and manages to beat EPS expectations, it could lead to a strong positive reaction from investors.

Bear Case

Conversely, if the company fails to provide encouraging updates on its drug development or reports larger-than-expected losses, it could result in a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What updates can management provide on the progress of clinical trials for key drug candidates?

Investors will closely watch for any developments that could indicate the potential success of these therapies, which are crucial for the company's future.

How does the company plan to address its recent EPS misses and improve financial performance?

Understanding management's strategy for improving profitability will be critical for investor confidence and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of recent clinical trial results, which could lead to a more favorable outlook than currently anticipated.

Supporting Evidence

The options market is pricing a significant move, indicating that investors expect volatility and potential surprises.

The company's history of beating EPS estimates suggests that there may be more positive news than analysts expect.

Key Risk

If clinical trial results show unexpected promise, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to turn clinical advancements into financial success.

Bull Confirmed If

A significant improvement in clinical trial results or an EPS beat could confirm the bull case.

Bear Confirmed If

A larger-than-expected EPS loss or disappointing trial updates would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±33.48%

Historical Avg

±2.9%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±33.5% while RCUS has averaged ±2.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

56.4%

Calls (400)P/C Ratio: 0.40Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arcus beats expectations, history suggests the stock could rise by an average of 1.35%, confirming investor optimism about its drug pipeline.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.

Miss

If the company misses expectations, history suggests a potential decline of around 4.57%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the progress of clinical trials and any upcoming milestones.
2Management's strategy for improving financial performance.
3Insights into potential partnerships or collaborations.
4Updates on market conditions and competitive landscape.
5Any changes in guidance or future outlook.